American Association for Cancer Research
bcd-23-0061_supplementary_data_3_suppsd3.xlsx (5.41 MB)

Supplementary Data 3 from ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma

Download (5.41 MB)
posted on 2024-01-25, 15:00 authored by Paola Neri, Benjamin G. Barwick, David Jung, Jonathan C. Patton, Ranjan Maity, Ines Tagoug, Caleb K. Stein, Remi Tilmont, Noemie Leblay, Sungwoo Ahn, Holly Lee, Seth J. Welsh, Daniel L. Riggs, Nicholas Stong, Erin Flynt, Anjan Thakurta, Jonathan J. Keats, Sagar Lonial, P. Leif Bergsagel, Lawrence H. Boise, Nizar J. Bahlis

KZF1 ChIP-seq peaks as determined with MACS2 relative to MM1S cells input.


Multiple Myeloma Research Foundation (MMRF)

National Cancer Institute (NCI)

United States Department of Health and Human Services

Find out more...

Paula and Rodger Riney Foundation

American Society of Hematology (ASH)



Immunomodulatory drugs (IMiD) are a backbone therapy for multiple myeloma (MM). Despite their efficacy, most patients develop resistance, and the mechanisms are not fully defined. Here, we show that IMiD responses are directed by IMiD-dependent degradation of IKZF1 and IKZF3 that bind to enhancers necessary to sustain the expression of MYC and other myeloma oncogenes. IMiD treatment universally depleted chromatin-bound IKZF1, but eviction of P300 and BRD4 coactivators only occurred in IMiD-sensitive cells. IKZF1-bound enhancers overlapped other transcription factor binding motifs, including ETV4. Chromatin immunoprecipitation sequencing showed that ETV4 bound to the same enhancers as IKZF1, and ETV4 CRISPR/Cas9-mediated ablation resulted in sensitization of IMiD-resistant MM. ETV4 expression is associated with IMiD resistance in cell lines, poor prognosis in patients, and is upregulated at relapse. These data indicate that ETV4 alleviates IKZF1 and IKZF3 dependency in MM by maintaining oncogenic enhancer activity and identify transcriptional plasticity as a previously unrecognized mechanism of IMiD resistance. We show that IKZF1-bound enhancers are critical for IMiD efficacy and that the factor ETV4 can bind the same enhancers and substitute for IKZF1 and mediate IMiD resistance by maintaining MYC and other oncogenes. These data implicate transcription factor redundancy as a previously unrecognized mode of IMiD resistance in MM.See related article by Welsh, Barwick, et al., p. 34.See related commentary by Yun and Cleveland, p. 5.This article is featured in Selected Articles from This Issue, p. 4